Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health (Nasdaq: GH) will present new data on its Guardant360 liquid biopsy test at the IASLC 2021 World Conference on Lung Cancer, highlighting its advantages in clinical decision-making for advanced lung cancer. The data aims to demonstrate the test's ability to rapidly identify actionable biomarkers, facilitating quicker treatment initiation compared to traditional tissue biopsies. Key presentations include studies on genomic profiling and treatment impact, scheduled from September 8-14, 2021.
Guardant Health, a precision oncology leader, will participate virtually in the Morgan Stanley Global Healthcare Conference on September 9, 2021, at 1:15 p.m. PT. Interested individuals can access a live and archived webcast via the company’s website. Guardant Health focuses on cancer care through advanced tests like Guardant360 and Guardant Reveal, aiming to improve patient outcomes and reduce healthcare costs. The company is dedicated to enhancing cancer screening, particularly for asymptomatic individuals.
Guardant Health, a leader in precision oncology, announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10 at 4:00 p.m. PT. The event will feature a fireside chat with the company’s management, accessible via a webcast on their website. Guardant Health specializes in revolutionary cancer testing technologies like Guardant360 and Guardant Reveal, aimed at improving clinical outcomes and reducing costs. Their innovations support comprehensive cancer care and screening programs to help combat cancer globally.
Guardant Health (Nasdaq: GH) has announced a new leadership structure to drive growth, appointing Helmy Eltoukhy and AmirAli Talasaz as co-CEOs. Eltoukhy will also serve as Chairman, while Meghan Joyce joins the Board as an Independent Director. This new structure aims to enhance focus on Oncology and Screening, following recent oncology product launches and a planned blood-based screening LDT in 2022. The leadership team emphasizes a commitment to innovative cancer solutions and improved patient outcomes, positioning Guardant as a potential leader in early cancer detection.
Guardant Health reported a revenue of $92.1 million for Q2 2021, up 39% year-over-year, with clinical testing revenue increasing 54%. The company performed 20,830 clinical tests and 3,653 biopharmaceutical tests. Gross profit rose to $62.2 million with a 68% gross margin. However, operating expenses surged to $159.8 million, driving a net loss of $97.6 million. Guardant maintains its 2021 revenue guidance of $360 million to $370 million, indicating 26% to 29% growth over 2020 amid ongoing COVID-19 uncertainties.
Fight Colorectal Cancer and Guardant Health will honor clinical researchers and advocates with the “Back to Screening Award for Research Advocacy Excellence.” This recognition takes place at the “Path to a Cure” event in December 2021, emphasizing efforts to revitalize colorectal cancer screening post-pandemic. The ECLIPSE trial, evaluating a blood test for colorectal cancer screening, aims for FDA approval. With only 66% of adults screened, the trial addresses a critical healthcare gap exacerbated by COVID-19, reflecting a pressing need for non-invasive solutions to combat rising colorectal cancer rates among younger populations.
Lunit, a leading AI startup in cancer solutions, secured a strategic investment of $26 million from Guardant Health (Nasdaq: GH). This collaboration aims to innovate the precision oncology landscape and enhance cancer diagnostics. Following this investment, Lunit is set to file for an initial public offering on the Korean Stock Exchange. Notably, Lunit's SCOPE platform demonstrated a 50% improvement in identifying patients suitable for immunotherapy at the ASCO 2021 meeting. Leaders from both companies expressed optimism about advancing cancer care through this partnership.
Guardant Health, Inc. (Nasdaq: GH) will report its financial results for Q2 2021 on August 5, 2021, after the market closes. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET, which will be available for live listening on the company’s website. Guardant Health focuses on precision oncology with proprietary tests like Guardant360® and Guardant Reveal™, aiming to improve patient outcomes and reduce healthcare costs across cancer care stages.
Guardant Health (Nasdaq: GH) has launched two innovative tests for late-stage cancer management: the Guardant360 Response and Guardant360 TissueNext. The Guardant360 Response is a blood-only test that detects changes in circulating tumor DNA (ctDNA), providing early treatment response indicators up to eight weeks prior to traditional methods. The Guardant360 TissueNext offers tissue testing to complement the blood test, ensuring comprehensive patient evaluation. These additions enhance the Guardant360 portfolio, aiming to optimize treatment selection and improve clinical outcomes.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
